Tag: Precision Medicine
-
Genetic and Inflammatory Predictors of Nondilated LV Cardiomyopathy Progression
Understanding Nondilated Left Ventricular Cardiomyopathy (NDLVC) Nondilated left ventricular cardiomyopathy (NDLVC) is a form of heart muscle disease characterized by a normal-sized left ventricle despite functional impairment. Unlike dilated cardiomyopathy, NDLVC can be more insidious, with patients remaining asymptomatic for longer periods or presenting with heart failure symptoms that are not easily attributed to classic…
-
Improving Diagnosis of Aortic Stenosis with Genetics and AI
New Frontiers in Aortic Stenosis Diagnosis Aortic stenosis (AS) is a progressive narrowing of the aortic valve that constrains blood flow from the heart to the body. It affects millions worldwide and remains a leading cause of cardiovascular morbidity and mortality when not identified and managed early. Traditional diagnostic approaches rely on echocardiography, clinical assessment,…
-
How Genetics and AI Are Transforming Aortic Stenosis Diagnosis
Overview: Aortic Stenosis Under the Lens Aortic stenosis, a narrowing of the aortic valve, restricts blood flow from the heart to the rest of the body. It is a common condition that can lead to heart failure if not detected and managed promptly. Traditionally, diagnosis relies on clinical evaluation, echocardiography, and imaging studies, but these…
-
Engineered Dendritic Cells Harness Tumor EVs to Boost Cancer Immunotherapy
Unlocking a New Layer of Cancer Immunotherapy Immunotherapy has transformed cancer care by reprogramming a patient’s own immune system to recognize and destroy malignant cells. Yet many tumors deploy stealth tactics that dull the scanning power of dendritic cells, the immune system’s sentinels. Recent advances in cellular engineering, however, are turning the tables. Researchers are…
-
Merlin CP-GEP Test from SkylineDx Outperforms Competitors in Melanoma Risk Stratification
New Evidence Places Merlin CP-GEP Test at the Forefront of Melanoma Risk Stratification In the fast-evolving field of melanoma care, precision risk assessment is critical for guiding surgical and medical decisions. SkylineDx has released new data indicating that its Merlin CP-GEP Test provides superior metastatic-risk stratification for melanoma patients, along with more accurate predictions of…
-
New blood test can detect and monitor lung cancer in real time
Revolutionizing lung cancer care with a real-time blood test A promising breakthrough from UK researchers promises to transform how clinicians detect and monitor lung cancer. The new blood test, described as a form of liquid biopsy, aims to provide real-time insights into tumor activity. By analyzing circulating tumor signals in a patient’s blood, doctors could…
-
Targeted mRNA Vaccines: Train Immune System to Fight Cancer
What are targeted mRNA vaccines and why do they matter for cancer? Cancer remains one of the leading health challenges worldwide, capable of adapting and hiding from conventional treatments. Targeted mRNA vaccines offer a new approach by teaching the immune system to recognize and destroy cancer cells specifically, while sparing healthy tissue. Unlike traditional chemotherapy,…
-
Targeted mRNA Vaccines: Training the Immune System to Fight Cancer
Introduction: A New Approach to Cancer Treatment Cancer remains a formidable health challenge worldwide. Traditional therapies like chemotherapy and radiation can fight tumors but often bring significant side effects and uneven success. A new era in cancer care is emerging: targeted mRNA vaccines that train the immune system to recognize and destroy cancer cells. By…
-
Gene Therapy Brings Hope for Child with Rare Parkinson’s
Hope Emerges from a Groundbreaking Gene Therapy In Singapore, a breakthrough in pediatric neuroscience is offering renewed hope to families affected by a rare Parkinson’s-like disease. A young patient, diagnosed soon after birth with a neurodegenerative condition characterized by stiffness, seizure-like episodes, and impaired motor and speech development, became the focus of an ambitious gene…
-
Lighthouse Pharmaceuticals to Present Phase 2 SPRING Trial of LHP588 at CTAD 2025
Overview of the SPRING Trial and LHP588 Lighthouse Pharmaceuticals, a Novato, California-based clinical-stage biopharmaceutical company, is poised to share new data from its Phase 2 SPRING trial of LHP588, a next-generation gingipain inhibitor designed to address P. gingivalis-positive Alzheimer’s disease. Gingipains are enzymes produced by the oral bacterium Porphyromonas gingivalis, which researchers have linked to…